Actions of sipatrigine, 202W92 and lamotrigine on R-type and T-type Ca2+ channel currents

European Journal of Pharmacology

Volumn 467, Issue 1-3, 2003, Pages 77-80

  Hainsworth, Atticus H ^a   McNaughton, Nicolle C L ^b   Pereverzev, Alexey ^c   Schneider, Toni ^c   Randall, Andrew D ^b  

^a DE MONTFORT UNIVERSITY   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Anticonvulsant; Antiepileptic drug; Ca2+ channel; Lamotrigine; Voltage activated

Indexed keywords

2,4 DIAMINO 6 (FLUOROMETHYL) 5 (2,3,5 TRICHLOROPHENYL)PYRIMIDINE; 202 W 92; ANTICONVULSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL R TYPE; CALCIUM CHANNEL T TYPE; LAMOTRIGINE; PROTEIN SUBUNIT; PYRIMIDINE DERIVATIVE; SIPATRIGINE; UNCLASSIFIED DRUG;

ALPHA CHAIN; ARTICLE; CALCIUM CURRENT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; EMBRYO; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0037466489     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01625-X     Document Type: Article

References (24)

1. 2+ channels by benzothiazepines and phenylalkylamines: class-specific pharmacology and underlying molecular determinants. Mol. Pharmacol. 51:1997;872-881.
2. Caputi L., Hainsworth A.H., Lavaroni F., Leach M.J., McNaughton N.C.L., Mercuri N.B., Randall A.D., Spadoni F., Swan J.H., Stefani A. Neuroprotective actions in vivo and electrophysiological actions in vitro of 202W92. Brain Res. 919:2001;259-268.
3. Coulter D.A., Huguenard J.R., Prince D.A. Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann. Neurol. 25:1989;582-593.
4. Crunelli V., Leresche N. Childhood absence epilepsy: genes, channels, neurons and networks. Nat. Rev., Neurosci. 3:2002;371-382.
5. Hainsworth A.H., Stefani A., Calabresi P., Smith T.W., Leach M.J. Sipatrigine (BW 619C89) is a neuroprotective agent and a sodium channel and calcium channel inhibitor. CNS Drug Rev. 6:2000;111-134.
6. Leach M.J., Lees G., Riddall D.R. Lamotrigine: mechanisms of action. Levy R.H., Mattson R.H., Meldrum B.S. Antiepileptic Drugs. 4th ed. 1995;861-869 Raven Press, New York, NY.
7. Lee S.C., Choi S., Lee T., Kim H.L., Chin H., Shin H.S. Molecular basis of R-type calcium channels in central amygdala neurons of the mouse. Proc. Natl. Acad. Sci. U. S. A. 99:2002;3276-3281.
8. Leresche N., Parri H.R., Erdemli G., Guyon A., Turner J.P., Williams S.R., Asprodini E., Crunelli V. On the action of the anti-absence drug ethosuximide in the rat and cat thalamus. J. Neurosci. 18:1998;4842-4853.
9. Matsuo F. Lamotrigine. Epilepsia. 40:1999;S30-S36.
10. McCabe P.H. New anti-epileptic drugs for the 21st century. Expert Opin. Pharmacother. 1:2000;633-674.
11. McNaughton N.C.L., Hainsworth A.H., Green P.J., Randall A.D. Inhibition of recombinant low-voltage-activated Ca(2+) channels by the neuroprotective agent BW619C89 (Sipatrigine). Neuropharmacology. 39:2000;1247-1253.
12. Mehrke G., Pereverzev A., Grabsch H., Hescheler J., Schneider T. Receptor-mediated modulation of recombinant neuronal class E calcium channels. FEBS Lett. 408:1997;261-270.
13. Meldrum B.S., Smith S.E., Lekieffre D., Chapman A.G., Graham J.L., Pearce P.C. Sodium-channel blockade and glutamate release: the mechanism of cerebroprotection by lamotrigine, BW1003C87 and BW619C89. Krieglstein J., Oberpichler-Schwenk H. Pharmacology of Cerebral Ischaemia. 1994;203-209 WVmbH, Stuttgart.
14. 2+ currents. Neuropharmacology. 37:1998;957-972.
15. Perez-Reyes E., Cribbs L.L., Daud A., Lacerda A.E., Barclay J., Williamson M.P., Fox M., Rees M., Lee J.H. Molecular characterization of a neuronal low voltage-activated T-type calcium channel. Nature. 391:1998;896-900.
16. 2+ channels. Mol. Cell. Neurosci. 14:1999;255-272.
17. Randall A.D., Tsien R.W. Contrasting biophysical and pharmacological properties of T-type and R-type calcium channels. Neuropharmacology. 36:1997;879-893.
18. Reddy N.L., Fan W., Magar S.S., Perlman M.E., Yost E., Zhang L., Berlove D., Fischer J.B., Burke-Howie K., Wolcott T., Durant G.J. Synthesis and pharmacological evaluation of N,N′-diarylguanidines as potent sodium channel blockers and anticonvulsant agents. J. Med. Chem. 41:1998;3298-3302.
19. Soong T.W., Stea A., Hodson C.D., Dubel S.J., Vincent S.R., Snutch T.P. Structure and functional expression of a member of the low voltage-activated calcium channel family. Science. 260:1993;1133-1136.
20. Tottene A., Volsen S., Pietrobon D. Alpha(1E) subunits form the pore of three cerebellar R-type calcium channels with different pharmacological and permeation properties. J. Neurosci. 20:2000;171-178.
21. Williams M.E., Marubio L.M., Deal C.R., Hans M., Brust P.F., Philipson L.H., MIller R.J., Johnson E.C., Harpold M.M., Ellis S.B. Structure and functional characterization of neuronal a1E calcium channel subtypes. J. Biol. Chem. 269:1994;22347-22357.
22. 2+ currents evoke transmitter release at a rat central synapse. Proc. Natl. Acad. Sci. U. S. A. 95:1998;4720-4725.
23. Xie X., Hagan R.M. Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy in bipolar disorder. Neuropsychobiology. 38:1998;119-130.
24. Yokoyama C.T., Westenbroek R.E., Hell J.W., Soong T.W., Snutch T.P., Catterall W.A. Biochemical properties and subcellular distribution of the neuronal class E calcium channel alpha 1 subunit. J. Neurosci. 15:1995;6419-6432.